Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

France’s Sanofi Pasteur Adopts “High State Of Readiness” To Produce Global Vaccine Defense Arsenal If H1N1 Evolves Into Pandemic: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Immediately after the Director-General of the World Health Organization raised the pandemic alert level from phase 4 to phase 5, just one step below notification of a global health threat, an influenza expert at Sanofi Pasteur outlined the French-based vaccine maker's response: moving into a "high state of readiness" to help create a worldwide vaccine defense to the speedening spread of H1N1. Sanofi Pasteur is a global power in terms of vaccine production, turning out 1.6 billion vaccine doses in 2008, and specialist Albert Garcia at Pasteur's headquarters in Lyon, France provided an overview on how the outfit's operations in the Americas, Europe and Asia could be mobilized in a worldwide fight against H1N1.

You may also be interested in...



China's Sinovac Just Steps Away From Crossing Global Finish Line In Race To Launch A/H1N1 Vaccine

BEIJING - Just days away from widely expected regulatory approval for an A/H1N1 vaccine, the Beijing-based Sinovac Biotech is now virtually guaranteed to become the first producer in the world to market a defense to the swine flu pandemic

China's Sinovac Just Steps Away From Crossing Global Finish Line In Race To Launch A/H1N1 Vaccine

BEIJING - Just days away from widely expected regulatory approval for an A/H1N1 vaccine, the Beijing-based Sinovac Biotech is now virtually guaranteed to become the first producer in the world to market a defense to the swine flu pandemic

Poised To Produce A/H1N1 Vaccine, Sanofi Pasteur Ramping Up Capacity In U.S., Developing Defense For Another Killer Virus

BEIJING - On standby to rapidly turn out a vaccine for A/H1N1 if the World Health Organization declares a continents-wide pandemic is emerging, scientists at Sanofi Pasteur are also working with the UN group to develop a defense for the tropical dengue virus, which has already killed far more people worldwide than the swine flu

Latest Headlines
See All
UsernamePublicRestriction

Register

SC071675

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel